Article Text

Download PDFPDF
Aciclovir prophylaxis after varicella zoster exposure in pregnancy
  1. Joanna Girling
  1. Chelsea and Westminster Hospital NHS Foundation Trust, West Middlesex University Hospital, Middlesex, UK
  1. Correspondence to Dr Joanna Girling, Chelsea and Westminster Hospital NHS Foundation Trust, West Middlesex University Hospital, Middlesex, UK; Joanna.Girling{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In the UK, recommendations for varicella zoster (VZ) vaccination limit its use to certain key groups including non-immune healthcare workers, some laboratory staff and immediate family members of immunocompromised patients.1 As it is a live vaccine it should never be given during pregnancy.1 VZ vaccination is not part of the UK national immunisation programme, despite evidence from other countries of a reduction in chickenpox morbidity and mortality, and in congenital and newborn varicella following introduction of a universal vaccination programme.2

Although the vast majority of people living in the UK develop natural immunity after mild childhood illness, around 10% of the adult population is not immune, and adults arriving from some countries have lower likelihood of immunity to VZ.1 Current national guidelines recommend pregnant women with neither previous VZ infection nor vaccination against VZ to avoid exposure and seek post exposure prophylaxis (PEP) if exposure does occur.3–5

Chickenpox is a potentially serious and life-threatening illness …

View Full Text


  • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

  • Provenance and peer review Commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.